Table 1.
Baseline characteristics of the 52 patients included in the study
| Characteristics | Values |
|---|---|
| Age (years) median (IQR) | 75 (64–83) |
| Female sex, n (%) | 31 (59.6) |
| NIHSS score at admission, median (IQR) | 19 (13–22) |
| Pre-stroke mRS, n (%) | |
| 0 | 44 (84.6) |
| 1 | 4 (7.7) |
| 2 | 4 (7.7) |
| Medical history, n (%) | |
| Hypertension | 34 (65.4) |
| Diabetes mellitus | 15 (28.8) |
| Atrial fibrillation | 13 (25) |
| Dyslipidemia | 28 (53.8) |
| Smoking | 12 (23.1) |
| Obesity | 5 (9.6) |
| Myocardial infarction or coronary artery disease | 13 (25) |
| Previous stroke or TIA | 8 (15.4) |
| Anticoagulation | 13 (25) |
| Antiplatelet | 9 (17.3) |
| ASPECTS at admission, median (IQR) | 9 (8–10) |
| Occlusion site, n (%) | |
| Left side | 30 (57.7) |
| ICA‑T | 14 (26.9) |
| MCA-M1 | 26 (50) |
| MCA-M2 | 12 (23.1) |
| Time from symptom onset or LTSW to arterial puncture (min), median (IQR) | 278 (170–419) |
| Door-to-groin time (min), median (IQR) | 70 (36–96) |
| QTM device used, n (%) | |
| Q3 | 5 (9.6) |
| Q4 | 7 (13.5) |
| Q5 | 19 (36.5) |
| Q6 | 21 (40.4) |
| Stent retriever used, n (%) | |
| Aperio Hybrid® | 27 (51.9) |
| Catch View® | 15 (28.8) |
| Embotrap II® | 5 (9.6) |
| NeVa® | 5 (9.6) |
| IV tPA administered, n (%) | 17 (32.7) |
IQR interquartile range, NIHSS National Institute of Health Stroke Scale score, mRS modified Rankin Scale score, TIA transient ischemic attack, ASPECTS Alberta Stroke Program Early CT Score, MCA-M1 ICA-T: intracranial carotid T occlusion, M1 segment of the middle cerebral artery, MCA-M2 M2 segment of the middle cerebral artery, LTSW last time seen well, QTM (MIVI Neuroscience, Inc., Eden Prairie, MN, USA), Aperio Hybrid® (Acandis company, Pforzheim, Germany), Catch View® (Balt, Montmorency, France), Embotrap II® (Cerenovus, Galway, Ireland), NeVa® (Vesalio, Nashville, TN, USA), IV tPA intravenous tissue plasminogen activator